Melanotan 1 and Melanotan 2 are often listed side by side and treated as near-identical, but at the molecular level they are two distinctly engineered analogs of the same parent peptide — α-melanocyte-stimulating hormone (α-MSH). One is linear and full-length; the other is cyclic and truncated. That single architectural choice is what separates their behavior at the melanocortin receptors in the published literature. This comparison covers what each molecule is, how their structures differ, and what receptor-pharmacology studies have characterized for each.
The shared starting point: α-MSH
Both compounds are derived from α-MSH, a 13-residue endogenous peptide in the melanocortin family. Native α-MSH is a linear sequence (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) that binds, with varying affinity, to a family of melanocortin receptors — designated MC1R through MC5R. Like many small linear peptides, the natural hormone is short-lived: enzymes degrade it quickly, and its activity at the receptor is correspondingly brief.
Both Melanotan analogs exist because researchers set out to address that fragility through deliberate structural modification. They took different routes to do so, and the two routes are precisely what distinguish the molecules.
Melanotan 1: a linear analog with two substitutions
Melanotan 1 — also known by the research name afamelanotide, or [Nle4, D-Phe7]-α-MSH (NDP-MSH) — keeps the full-length, linear backbone of α-MSH. It is not truncated or cyclized. Instead it carries two targeted amino-acid substitutions within that intact chain:
- Position 4: the native methionine is replaced with norleucine (Nle), removing an oxidation-prone residue.
- Position 7: the L-phenylalanine is replaced with its mirror-image D-phenylalanine (D-Phe), a stereochemical change that resists the enzymes that would normally cleave the L-form.
These two substitutions leave the molecule’s overall shape and length essentially that of the parent hormone, while making it far more durable. In early melanophore research models, a single administration of [Nle4, D-Phe7]-α-melanotropin produced pigment-cell dispersion in frog and lizard skin that persisted for weeks — an effect the authors measured as dramatically more prolonged than that of the natural hormone, which lasted only days (Hadley et al., Science, 1981). Melanotan 1 is therefore best understood as α-MSH with a stabilized but otherwise preserved linear structure.
Melanotan 2: a cyclic, truncated analog
Melanotan 2 takes a fundamentally different structural approach. Rather than preserving the full chain, it is a shortened, ring-closed peptide. Its design, reported in the foundational synthesis work, started from the same superpotent Nle4/D-Phe7 lineage and then truncated the sequence and joined two side chains together to form a lactam bridge — a covalent amide link between an aspartate (position 5) and a lysine (position 10) residue (Al-Obeidi et al., J Med Chem, 1989).
The consequences of that cyclization are structural:
- Cyclic, not linear: the lactam bridge constrains the peptide into a fixed ring conformation rather than a freely flexible chain.
- Truncated: residues are removed from both ends, so Melanotan 2 is a compact heptapeptide rather than a 13-residue chain.
- Conformationally locked: the ring restricts the molecule to the shape thought to be active, which the design study associated with high potency in skin bioassays.
In short, where Melanotan 1 is a lightly edited copy of the natural hormone, Melanotan 2 is a rebuilt, cyclized fragment of it. That is the core structural distinction between the two.
Receptor pharmacology: how the structures behave at melanocortin receptors
The structural divergence maps onto how each analog has been characterized at the melanocortin receptor subtypes in binding studies. This is the part of the comparison most often summarized as “selectivity,” and the published data describe a meaningful contrast.
Melanotan 2 is characterized as broadly non-selective. When the cyclic lactam analog (MTII) was tested on cells expressing the human MC1, MC3, MC4, and MC5 receptors, it bound across the subtypes rather than confining itself to one — the study measured it as a high-affinity ligand spanning multiple melanocortin receptors, including MC4R (Schiöth et al., Peptides, 1997). The conformationally locked ring, in other words, is compatible with engagement across the receptor family.
Melanotan 1 / NDP-MSH has been studied largely through the lens of MC1R. A receptor-mutation study examined how the D-Phe7 stereoisomer engages the melanocortin-1 receptor and found that it relies on different binding contacts than native α-MSH: alanine mutations that sharply reduced binding of the natural L-isomer left binding of [Nle4, D-Phe7]-α-MSH essentially unchanged, indicating the two stereoisomers attach to the receptor at partly distinct points (Frändberg et al., Biochem Biophys Res Commun, 1994). This is the kind of receptor-level detail that explains why the single D-Phe7 substitution so strongly alters the molecule’s interaction with MC1R.
The practical framing for a structural comparison is this: the cyclic, truncated Melanotan 2 is the broader melanocortin-receptor agonist in published binding work, engaging multiple subtypes including MC4R, whereas the linear, full-length Melanotan 1 lineage has been characterized primarily through its distinctive, stereoselective interaction with MC1R. The difference is a consequence of architecture — ring-constrained heptapeptide versus stabilized full-length chain.
Side-by-side summary
- Parent peptide: both are analogs of α-MSH.
- Backbone — Melanotan 1: linear, full-length (13-residue), research name afamelanotide / [Nle4, D-Phe7]-α-MSH.
- Backbone — Melanotan 2: cyclic, truncated heptapeptide closed by an Asp5–Lys10 lactam bridge.
- Key substitutions: Melanotan 1 uses Nle4 and D-Phe7 within an intact chain; Melanotan 2 builds on that lineage but adds truncation and cyclization.
- Receptor profile in cited studies: Melanotan 2 binds broadly across MC1/MC3/MC4/MC5; the Melanotan 1 / NDP-MSH lineage is characterized chiefly through a stereoselective MC1R interaction.
Frequently asked questions
What is the structural difference between Melanotan 1 and Melanotan 2?
Melanotan 1 (afamelanotide, [Nle4, D-Phe7]-α-MSH) is a linear, full-length analog of α-MSH with two amino-acid substitutions. Melanotan 2 is a cyclic, truncated heptapeptide closed by a lactam bridge between its position-5 and position-10 residues. Linear versus cyclic is the core distinction.
Is Melanotan 1 the same as afamelanotide?
Yes. “Melanotan 1,” “afamelanotide,” and “[Nle4, D-Phe7]-α-MSH” (NDP-MSH) are names for the same linear α-MSH analog described in the research literature.
Which Melanotan analog is more selective for a single melanocortin receptor?
In published binding work, Melanotan 2 (the cyclic lactam analog) was measured as a broad, non-selective ligand across the MC1, MC3, MC4, and MC5 receptors (Schiöth et al., 1997). The Melanotan 1 / NDP-MSH lineage has instead been characterized chiefly through its distinctive interaction with the MC1 receptor (Frändberg et al., 1994).
Why does Melanotan 2 have a ring structure?
Its lactam bridge — a covalent link between an aspartate and a lysine side chain — was introduced during its design to lock the peptide into a fixed conformation. The synthesis study associated this cyclized, conformationally constrained ring with high potency in skin bioassays (Al-Obeidi et al., 1989).
What does the D-Phe7 substitution do at the receptor level?
Replacing the native L-phenylalanine at position 7 with its D-isomer changes how the peptide contacts the MC1 receptor. A mutation study found the D-Phe7 form attaches at partly different receptor points than native α-MSH, so contacts that mattered for the natural hormone did not reduce binding of the analog (Frändberg et al., 1994).
Are Melanotan 1 and Melanotan 2 interchangeable?
No. They are different molecules — linear full-length versus cyclic truncated — with different characterized receptor-binding profiles in the published research. They are related by a common parent peptide, not equivalent.
References
- Hadley ME, et al. Calcium-dependent prolonged effects on melanophores of [4-norleucine, 7-D-phenylalanine]-alpha-melanotropin. Science. 1981. PMID: 6973820.
- Al-Obeidi F, et al. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. Journal of Medicinal Chemistry. 1989. PMID: 2555512.
- Frändberg PA, et al. Evidence for alternate points of attachment for alpha-MSH and its stereoisomer [Nle4, D-Phe7]-alpha-MSH at the melanocortin-1 receptor. Biochemical and Biophysical Research Communications. 1994. PMID: 8060302.
- Schiöth HB, et al. Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH analogues for the melanocortin receptor subtypes. Peptides. 1997. PMID: 9357059.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
